BioLine Rx (FRA:YP2) Inventory Turnover: 0.04 (As of Mar. 2026)

What is BioLine Rx Inventory Turnover?

BioLine Rx FRA:YP2 -0.79% 21 Inventory Turnover is 0.04 as of Mar. 2026. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. BioLine Rx's Cost of Goods Sold for the three months ended in Mar. 2026 was €0.08 Mil. BioLine Rx's Average Total Inventories for the quarter that ended in Mar. 2026 was €1.85 Mil. BioLine Rx's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.04.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. BioLine Rx's Days Inventory for the three months ended in Mar. 2026 was 2,033.89.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BioLine Rx's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 4.48.

BioLine Rx (FRA:YP2) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BioLine Rx's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2026 )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
	=	1.85	/	0.083	*	365 / 4
	=	2,033.89

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BioLine Rx's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	1.85	/	0.413
	=	4.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

BioLine Rx Inventory Turnover Related Terms

BioLine Rx Inventory Turnover Historical Data

* Premium members only.

The historical data trend for BioLine Rx's Inventory Turnover can be seen below:

BioLine Rx Inventory Turnover Chart

BioLine Rx Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Inventory Turnover

Get a 7-Day Free Trial

0.00

1.89

3.69

0.08

BioLine Rx Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Inventory Turnover	Get a 7-Day Free Trial															0.01	0.02	0.03	0.02	0.04

21GF Score

BioLine Rx Ltd FRA:YP2

Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BioLine Rx Inventory Turnover Calculation

BioLine Rx's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

	Inventory Turnover (A: Dec. 2025 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2025 )	/ (	(Total Inventories (A: Dec. 2024 )	+	Total Inventories (A: Dec. 2025 ))	/	count )
=	0.197	/ (	(3.003	+	1.834)	/	2 )
=	0.197	/	2.4185
=	0.08

BioLine Rx's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

	Inventory Turnover (Q: Mar. 2026 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2026 )	/ (	(Total Inventories (Q: Dec. 2025 )	+	Total Inventories (Q: Mar. 2026 ))	/	count )
=	0.083	/ (	(1.834	+	1.866)	/	2 )
=	0.083	/	1.85
=	0.04

Frequently Asked Questions Learn more about Inventory Turnover →

What does a Inventory Turnover of 0.04 mean?

BioLine Rx (FRA:YP2) has a Inventory Turnover of 0.04 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on BioLine Rx and its competitors.

Is BioLine Rx's Inventory Turnover too high?

BioLine Rx's current Inventory Turnover is 0.04. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.

How does BioLine Rx's Inventory Turnover compare to VRTX and REGN?

BioLine Rx's Inventory Turnover of 0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventory Turnover for a Biotechnology company?

A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventory Turnover mean?

A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on BioLine Rx and its competitors. BioLine Rx's current Inventory Turnover is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BioLine Rx stock overvalued right now?

BioLine Rx (FRA:YP2) has a current Inventory Turnover of 0.04. The current Inventory Turnover is 0.04. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventory Turnover calculated?

Inventory Turnover is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current Inventory Turnover is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Industry Healthcare Biotechnology

Comparable Companies XTAE:CBI XTAE:BOLT XTAE:CANF XTAE:PPBT XTAE:XTLB XTAE:EVGN XTAE:HDST-M XTAE:MTLF XTAE:GFC-M VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA XKRX:068270

Other Exchanges BLRX:USA BLRX:Israel

Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website https://www.biolinerx.com

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

21GF Score

Get the complete analysis for FRA:YP2

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52

Price

View FRA:YP2 Analysis

See Inventory Turnover data for all stocks →